GAMA
XLRN

Graticule Asia Macro Advisors’s Acceleron Pharma XLRN Stock Holding History

Graticule Asia Macro Advisors’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-23,440
Closed -$3M – 230
2020
Q4 		$3M Buy
+23,440
New +$2.75M 1.44% 22
2020
Q2 		– Sell
-48,700
Closed -$4.38M – 55
2020
Q1 		$4.38M Buy
+48,700
New +$3.79M 3.2% 12

Other funds holding XLRN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Graticule Asia Macro Advisors's XLRN Position: Q1 2021 in Review

Graticule Asia Macro Advisors sold out of Acceleron Pharma (XLRN) in Q1 2021, closing a stake of 23,440 shares — an estimated $3M sold.

Graticule Asia Macro Advisors first reported a position in XLRN in Q1 2020 and held it in 2 quarters. The position peaked at $4.38M in Q1 2020. 256 funds tracked by Wall St. Rank hold XLRN as of Q1 2021.

  • Graticule Asia Macro Advisors reported no remaining Acceleron Pharma position as of Q1 2021 after selling out during the quarter.
  • Graticule Asia Macro Advisors sold 23,440 Acceleron Pharma shares in Q1 2021, an estimated $3M.
  • Graticule Asia Macro Advisors first reported a position in Acceleron Pharma in Q1 2020 and held it in 2 quarters.
  • Graticule Asia Macro Advisors's Acceleron Pharma position peaked at $4.38M in Q1 2020.
  • 256 funds tracked by Wall St. Rank held Acceleron Pharma as of Q1 2021.

Based on Graticule Asia Macro Advisors's 13F filing for Q1 2021, filed 17 May 2021.